TG Therapeutics (NASDAQ:TGTX – Get Rating)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Monday, Zacks.com reports. Cantor Fitzgerald also issued estimates for TG Therapeutics’ FY2022 earnings at ($3.60) EPS.
Several other equities research analysts have also issued reports on the company. Zacks Investment Research raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 26th. StockNews.com assumed coverage on TG Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating for the company. HC Wainwright decreased their target price on TG Therapeutics from $68.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, April 18th. Finally, B. Riley decreased their target price on TG Therapeutics from $35.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, April 19th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $22.75.
Shares of TGTX opened at $5.71 on Monday. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.28. The business’s fifty day moving average is $8.62 and its 200 day moving average is $15.12. TG Therapeutics has a 12-month low of $5.58 and a 12-month high of $41.00. The stock has a market cap of $824.82 million, a P/E ratio of -2.17 and a beta of 2.25.
A number of institutional investors and hedge funds have recently made changes to their positions in TGTX. Moors & Cabot Inc. purchased a new stake in TG Therapeutics in the 3rd quarter worth about $53,000. Exane Derivatives purchased a new position in TG Therapeutics during the 1st quarter valued at about $54,000. Baldwin Brothers LLC MA grew its holdings in TG Therapeutics by 250.0% during the 1st quarter. Baldwin Brothers LLC MA now owns 7,000 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 5,000 shares in the last quarter. PSI Advisors LLC purchased a new position in TG Therapeutics during the 3rd quarter valued at about $70,000. Finally, Prospera Financial Services Inc purchased a new position in TG Therapeutics during the 1st quarter valued at about $70,000. 70.52% of the stock is owned by institutional investors.
About TG Therapeutics (Get Rating)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.
- Get a free copy of the StockNews.com research report on TG Therapeutics (TGTX)
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.